Skip to main content
OpenTrials
Completed

NCT Number: NCT07024589

First-in-Human Trial of Oral AN2-502998

First-in-Human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy Volunteers Chagas Disease Euglenozoa Infections Infections Parasitic Diseases Protozoan Infections Trypanosomiasis Vector Borne Diseases

Age range

18 year–55 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Nucleus Network

Melbourne, Victoria, 3004, Australia

About this study

First-in-human Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998

Part A (SAD; Groups SAD1-SAD6):

Part A is the Single Ascending Dose (SAD) portion of the trial that will be conducted in approximately 48 healthy adults in approximately 6 groups. Eight participants in each group will be randomized in a 6:2 ratio to receive a single dose of AN2-502998 or matching PBO, respectively (6 AN2-502998:2 PBO).

Part B (MAD; Groups MAD1-MAD3):

Part B is the Multiple Ascending Dose (MAD) portion of the trial that will be conducted in approximately 24 healthy adults in approximately 3 groups. Eight participants in each group will be randomized in a 6:2 ratio to receive multiple doses of AN2-502998 or matching PBO (6 AN2 502998:2 PBO) QD for 10 days.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Male or female aged 18 to 55 years, inclusive, at Screening
  • Willing and able to provide written informed consent
  • Willing and able to comply with all trial assessments and adhere to the protocol schedule
  • BMI between ≥18 and <32 kg/m2 (inclusive); BMI is calculated as weight measured in kilograms (kg) divided by the square of height measured in meters (m)
  • If female, must:
  • Be of nonchildbearing potential defined as either postmenopausal for ≥2 years or surgically sterile (bilateral salpingectomy, bilateral oophorectomy, or hysterectomy); postmenopausal is defined as amenorrheic for ≥1 year in the absence of other biological causes, age appropriate, and has a FSH level during Screening indicating a postmenopausal state; AND
  • Have negative results for pregnancy tests performed as follows:

i. Urine specimen obtained during Screening, and ii. Serum specimen obtained on Study Day -1

  • If male and sexually active with a female of childbearing potential, must be surgically sterile or agree to practice at least 1 of the following effective forms of contraception up to 90 days after the last dose of study drug, starting with Study Day 1:
  • Partner(s) using an IUD
  • Partner(s) using oral, injected, or implanted methods of hormonal contraceptives
  • Partner(s) with bilateral tubal occlusion
  • Total abstinence from sexual intercourse as the preferred lifestyle of the participant; periodic abstinence is not acceptable
  • If male, must agree to use a male condom during intercourse to avoid potential drug exposure to the partner up to 90 days after the last dose of study drug, starting with Study Day 1
  • If female, must agree to use a male condom during heterosexual intercourse to avoid potential drug exposure to the partner up to 90 days after the last dose of study drug, starting with Study Day 1
  • Agree to not donate sperm (males) or ova (females) from Screening until 90 days after the last dose of study drug
  • Medically healthy with no significant clinical medical history, physical examination findings, laboratory results, vital signs, or 12-lead ECG findings, as deemed by the Investigator (or delegate)

Exclusion criteria

  • History of significant sensitivity to any drug, including any excipients used in AN2-502998
  • Requirement for any over-the-counter and/or prescription medication, vitamins and/or herbal supplements
  • Use of any medications (prescription or over-the-counter), vitamins, and/or herbal supplements within the 2-week period prior to the first dose of study drug administration or within 5 half-lives of the respective medication, whichever is longer
  • Receipt of any drug by injection, including vaccinations, within 30 days (for vaccinations) or a period defined by 5 half-lives, whichever is longer, prior to study drug administration
  • If female, is pregnant or breastfeeding
  • Positive test result for HBsAg, HCV Ab, HIV Ab, or HIV Ag at Screening; negative HIV status will be confirmed at Screening
  • ALT, AST, or total bilirubin with direct bilirubin >ULN for the reference laboratory at Screening
  • CrCl (Cockcroft-Gault formula), Hgb, Hct, WBC, neutrophil, or platelet count <LLN for the reference laboratory at Screening, unless deemed not CS by the Investigator
  • Fasting glucose ≥5.6 mmol/L
  • QTcF interval duration >450 msec for females or >430 msec for males at Screening
  • Recent (3-month) history of drug or alcohol abuse that could preclude adherence to the protocol
  • History of regular alcohol consumption exceeding 7 drinks/week for females or 14 drinks/week for males (1 drink = 5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer, or 1.5 ounces [45 mL] of hard liquor) within 6 months prior to Screening
  • Positive screen for drugs of abuse, alcohol, or cotinine at Screening and Study Day -1
  • History of seizures, diabetes, or cancer (except basal cell carcinoma of the skin)
  • Current clinically significant cardiovascular, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, neurologic or thyroid disease, or any uncontrolled medical illness or psychiatric disease or disorder
  • Past history of epilepsy; any clinically significant cardiovascular, respiratory (except mild asthma), renal, hepatic, gastrointestinal, hematologic, neurologic, or thyroid disease; or any uncontrolled medical illness or psychiatric disease or disorder
  • History of gastric surgery, vagotomy, bowel resection, cholecystectomy, or any surgical procedure or medical condition that might interfere with gastrointestinal motility, pH, or absorption
  • Donation or loss of 550 mL or more blood volume (including plasmapheresis) within 4 weeks prior to study drug administration or receipt of a transfusion of any blood product within 8 weeks prior to study drug administration
  • Receipt of any investigational product within a period equal to 10 half-lives of the product, if known, or a minimum of 6 weeks prior to study drug administration
  • Consumption of alcohol within the 72 hours prior to study drug administration
  • Consumption of grapefruit, star fruit, Seville oranges, or products containing any of these ingredients within the 10-day period prior to study drug administration
  • Use of inhaled nicotine, tobacco, or marijuana products within the 6 months prior to study drug administration
  • Current enrollment in another clinical trial

Treatment and study plan

AN2-502998

Drug

Oral Capsule

Placebo

Drug

Oral Capsule

Primary outcomes

  1. Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion for a Single Dose

    Time frame: Day 1 through last follow-up (9 Days after single dose)

    Incidence, relatedness, and severity of adverse events

  2. Evaluate Physical Examination Abnormalities from Baseline Through Study Completion for a Single Dose

    Time frame: Day 1 through last follow-up (9 Days after single dose)

    Incidence of physical exam abnormalities

  3. Evaluate Change in Vital Signs from Baseline Through Study Completion for a Single Dose

    Time frame: Day 1 through last follow-up (9 Days after single dose)

    Incidence of changes in blood pressure, pulse, respiratory rate, and temperature

  4. Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion for a Single Dose

    Time frame: Day 1 through last follow-up (9 Days after single dose)

    Incidence of changes in 12-lead ECG parameters from baseline

  5. Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion for a Single Dose

    Time frame: Day 1 through last follow-up (9 Days after single dose)

    Incidence of changes in clinical laboratory measurements from baseline

  6. Evaluate the Incidence of Treatment Emergent Adverse Events at Baseline and Through Study Completion for Multiple Doses

    Time frame: Day 1 through last follow-up (10 Days after last dose)

    Incidence, relatedness, and severity of adverse events

  7. Evaluate Physical Examination Abnormalities from Baseline Through Study Completion for Multiple Doses

    Time frame: Day 1 through last follow-up (10 Days after last dose)

    Incidence of physical exam abnormalities

  8. Evaluate Change in Vital Signs from Baseline Through Study Completion for Multiple Doses

    Time frame: Day 1 through last follow-up (10 Days after last dose)

    Incidence of changes in blood pressure, pulse, respiratory rate, and temperature

  9. Evaluate Changes in 12-lead ECG Measurements from Baseline Through Study Completion for Multiple Doses

    Time frame: Day 1 through last follow-up (10 Days after last dose)

    Incidence of changes in 12-lead ECG parameters from baseline

  10. Evaluate Changes in Clinical Laboratory Tests from Baseline Through Study Completion for Multiple Doses

    Time frame: Day 1 through last follow-up (10 Days after last dose)

    Incidence of changes in clinical laboratory measurements from baseline

  11. Characterize the PK Profile of AN2-502998: Maximum Plasma Concentration

    Time frame: Day 1 through last follow-up (3 Days after last dose)

    Determination of the maximum plasma concentration (Cmax)

  12. Characterize the PK Profile of AN2-502998: Time to Maximum Plasma Concentration

    Time frame: Day 1 through 3 days after last dose

    Determination the time to maximum plasma concentration (Tmax)

  13. Characterize the PK Profile of AN2-502998: Terminal Half-Life

    Time frame: Day 1 through 3 days after last dose

    Determine the apparent terminal half-life (t½)

  14. Characterize the PK Profile of AN2-502998: Area Under Plasma Concentration Curve

    Time frame: Day 1 through 3 days after last dose

    Area under plasma concentration-time curve from zero to a designated dosing interval

  15. Characterize the PK Profile of AN2-502998: Apparent Plasma Clearance

    Time frame: Day 1 through 3 days after last dose

    Apparent plasma clearance of drug after extravascular administration CL/F

Sponsors and collaborators

Lead sponsor

AN2 Therapeutics, Inc

Industry

Registry information

Official study title

A Phase 1, Single-Center, Randomized, Blinded, Placebo-Controlled Trial in Healthy Adults to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of Oral AN2-502998

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jun 17, 2025
Registry last updated
Apr 30, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.